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Hyaluronan, a glycosaminoglycan, abundant in the tumour microenvironment, is a key player in many processes associated with cancer. 
Recently the cancer resistance of the naked mole rat has been attributed to the presence of  an ultra-high molecular weight form of this 
molecule. The physical properties of this multifunctional biopolymer have been extensively studied in the context of synovial joints. 
However, relatively little has been reported with regard to the soft matter properties of hyaluronan in relation to cancer. In this review we 10 
examine the role of hyaluronan in cancer, paying particular attention to its mechanical interactions with malignant cells and its soft matter 
properties. In addition we discuss the use of hyaluronan based gels to study cancer invasion as well as nanoparticle based strategies for 
disease treatment. 
Introduction 
Cancer in humans is very common with a third of us developing 15 
some form of it during our lifetime. However a number of animal 
species have been described to have either a very low incidence or 
resistance to cancer.1 This can usually be attributed to extra tumour 
suppressive cell signalling pathways, however there is one 
exception. The naked mole rat is a remarkable creature in that it 20 
has an exceptionally long life span for its size and is resistant to 
cancer.2 Thus when a breakthrough paper was published 
attributing the naked moles cancer resistant to the production of an 
ultra-high molecular weight glycosaminoglycan3, the inevitable 
wild speculation, regarding injecting humans with this as a 25 
preventative measure against future development of cancer was 
brandished. 
It turns out that this molecule, albeit in a lower molecular weight 
form, is a ubiquitous extracellular matrix (ECM) molecule in 
humans, and has been attributed to play important roles in many 30 
aspects of cancer pathology.4–10 These roles can be roughly split 
into two categories, although there is obvious crossover. The first 
is biological in nature, involving the binding of hyaluronan with 
cell membrane based receptors to initiate signalling and 
subsequent gene expression. The second is mechanical, relating to 35 
purely physical interactions regulating cell adhesion, mobility and 
invasion.   
The cancer cell microenvironment comprises non-cancerous cells, 
ECM biomolecules and vasculature. Cues within the 
microenvironment can regulate the various processes involved in 40 
cancer progression.11 Within the microenvironment the ECM, a 
"glue like" substance, has an intricate relationship with the cells in 
which it encloses.5,12–14 Abnormality of the ECM within the 
microenvironment is a characteristic of cancer, and abnormal 
levels of hyaluronan within the ECM are indicative of a poor 45 
prognosis for the patient.15–20. A symbiotic relationship exists 
whereby tumour cells have the ability to remodel the ECM around 
them, and the matrix has the ability to affect the behaviour of the 
tumour cells.21–24 Soft matter properties of the matrix are an 
important factor in the mechanotransduction between these two 50 
environments.25 A second hyaluronan rich interface exists called 
the pericellular matrix. This micron thick cell coating can also play 
an important role in the cell mobility necessary for metastatic 
spread .26  
A somewhat confusing paradox exists in that the presence of 55 
hyaluronan has been attributed to cancer resistance in the naked 
mole rat, whereas the presence of hyaluronan in human 
malignancies is seen as an indicator of poor prognosis. However in 
the human case the hyaluronan has been cleaved into fragments of 
varying molecular weights, which themselves may have disruptive 60 
effects on cell/microenvironment linkages.27,28 Given this strong 
link between hyaluronan abundance/abnormality in cancer, an 
opportunity exists to target hyaluronan in the 
microenvironment.29,30 Such an extra line of attack is particularly 
attractive in cancers that have been hard to treat with conventional 65 
therapies, for example pancreatic and colon cancer.31,32  
In this review we will concentrate on the mechanical role of 
hyaluronan in cancer in so far as it can be deconvoluted from its 
function in cell signalling. This will lead to a discussion on the 
hyaluronan biomaterials that can mimic the tumour 70 
microenvironment and how hyaluronan-cell interactions can be 
exploited for nanoparticle based therapy. 
 
Structure and synthesis of hyaluronan 
Hyaluronan, also known as hyaluronic acid (HA), is a linear 75 
glycosaminoglycan. It is comprised of a repeating disaccharide 
 2  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
unit, which is composed of N-acetyl-glucosamine and glucoronic 
acid. Depending on function and location, its molecular weight (in 
humans) can vary between 0.5 to 2 MDa.33–35 This compares with 
naked mole rat hyaluronan (NMR-HA) which varies from 6 to 12 
MDa.3 The molecular weight of this biopolymer determines its 5 
physicochemical properties and these determine its function.36 In 
contrast to most other glycosaminoglycans which are produced in 
the Golgi apparatus and attached to other proteins, HA is 
synthesised in the inner cell membrane and extrudes out of the cell 
surface as further polymer units are added,7,37(Fig.1). In eukaryotic 10 
cells, there are 3 main enzymes identified which synthesise HA 
into different sizes: Hyaluronan synthase (HAS) 1, 2 and 3.38 These 
different isoforms of HA have been attributed to specific roles in 
normal biological processes. HAS3 is the most active enzyme 
leading to the production of large amounts of low molecular weight 15 
HA (0.5-1 MDa) required for normal cellular processes (growth 
and tissue repair). It is in itself a key component of the ECM with 
roles including regulation of tissue homeostasis, resistance to 
compressive tissue forces, and lubrication of articular joint 
surfaces. HAS2 is particularly active during embryonic 20 
development producing a high molecular weight HA (2 MDa), 
important for facilitating co-ordination of numerous essential 
cellular processes during early development. HAS1 is the least 
active enzyme producing HA of similar weight to HAS2 and its 
roles in health and disease remain relatively poorly understood.39 25 
 
 
Fig. 1 Hyaluronan is synthesised via a transmembrane located enzyme, 
hyaluronan synthase and is encompassed amongst the extracellular 
matrix. Its main receptor is CD44 and this linkage between the ECM and 30 
the cell is fundamental to many aspects of cancer pathology. The balance 
between hyaluronan production and destruction may be key to 
understanding this role. 
 
Interaction with cell membrane receptors 35 
Beyond the oncological event that transforms a cell into 
malignancy, the processes involved in cancer progression have 
both biological and mechanical origins. HA interacts with cells 
though transmembrane receptors, the main such receptor being 
CD4440,41, (Fig.1). It is these linkages and others like these, that 40 
regulate the adhesion and mobility of cells.42–44 There are of course 
other ECM-cell interactions45–47 for example those involving the 
protein fibronectin and the cell surface receptor integrin.48 The 
complex interactions between CD44 and HA have received 
intensive investigation including the role for membrane bound 45 
enzymes, which can cleave the CD44/HA complex and therefore 
facilitate cancer cell invasion.49 Fig. 2 shows how a cancerous cell 
in a human can break through an HA rich matrix and invade into a 
blood vessel via remodelling of its ECM. Enzymes degrading the 
HA and enzymes cleaving the CD44 receptor create a path for cell 50 
movement.  
 
 
Fig. 2 Remodelling of the hyaluronan rich matrix by cancer cells leading to 
invasion. In healthy cells CD44 receptors bind to hyaluronan in the matrix. 55 
Cancerous cells over express the membrane bound enzymes MMPs which 
cleave CD44 receptors. They also over produce the enzyme hyaluronidase 
which digests hyaluronan into smaller fragments. In this way the cancer 
cells can "break" through the matrix and invade into the circulatory 
system. 60 
 
Soft Matter Properties of HA 
Given the importance of intermolecular and mechanical 
interactions both within the ECM and with the cell membrane, 
understanding the soft matter properties of HA is critical to 65 
determining its biological function. These can be examined at both 
the gross and microscopic levels. A particular characteristic of HA 
containing solutions are their high viscosity50 and their ability to 
form cross-linked networks.51  This coupled with HA's ability to 
form gel like structures has been linked to increased density and 70 
fluid pressure in the tumour microenvironment, a consequence of 
which is increased resistance to chemotherapy.52,53  
HA has an established biological role in the dissemination of 
cancer cells to distant sites with the mechanics of circulating 
tumour cells adhering to the blood vessel wall critical to the initial 75 
steps of metastasis. An elegant method for elucidating these 
mechanical interactions involves microfluidic experiments which 
can reveal the behaviour of cancer cells under flow conditions, 
either encountering a cultured layer of endothelial cells or 
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immobilized biomolecules.54 Such model systems can represent 
the binding of cancer cells to endothelial cells in blood vessels, a 
critical step in metastasis.55 When encountering HA coated 
surfaces various types of cancer cells exhibit characteristic rolling 
and adhesion (Fig. 3). If CD44 receptors are blocked such rolling 5 
and adhesion is prevented, thus proving the importance of this 
interaction in phenomena related to metastatsis.56–58 The nature of 
this ligand receptor linkage is force dependent, meaning it has the 
ability to regulate cell rolling via force induced conformational 
changes in the CD44.59  10 
Much can be learnt about the mechanics and assembly of HA when 
examined at the single molecule level. Atomic force microscopy 
(AFM) reveals that HA can adopt a number of different 
conformations when adsorbed onto surfaces. In tapping mode, 
AFM reveals branched structures for high molecular weight HA 15 
with both intramolecular and intermolecular interactions.60,61 
Force spectroscopy, the unfolding of single biomolecules with an 
AFM tip, has shown HA to exhibit hydrogen bonding networks in 
aqueous solutions62 with the molecules undergoing a non-random 
to random coil transition upon heating to 46 °C. and Ssingle 20 
molecule stretching using an optical trap has allowed the 
measurement of persistence length, a measure of molecular 
stiffness, to be established.63 This was found to be 4.5 ± 1.2 nm, 
indicative of a single molecule measurement. However given the 
tendency of HA to form branched and network structures a more 25 
useful quantity would that be the persistence length of higher order 
fibrous structures.  Force spectroscopy has also 
measuredquantified the tensile strength of the CD44-HA bond.64 
These single molecule measurements revealed a rupture force of 
between 70 and 80 pN depending on contact duration. For 30 
comparison these were significantly higher than the rupture 
strength of the CD44 - fibrinogen bond.  Extending this 
methodology further by attaching HA molecules to an AFM 
cantilever, it has been possible to examine the forces of interaction 
between HA and live glioma cells.65 As well as binding with CD44 35 
and other membrane based receptors, HA can interact directly with 
lipids.66 Evidence for these non -specific interactions have been 
observed in the interaction of HA with liposomes, giving rise to 
cylinder and sheet like super structures .67 It has also been proposed 
that hydrophyllic regions of HA could attract the polar head groups 40 
of phospholipids68, a phenomenon which could explain the 
association of hayaluronanHA with cell membranes and by 
extension tumour cell membranes.  
Using soft matter approaches to assemble model systems can help 
deconvolute physical interactions from biological. This has been 45 
achieved by reconstituting CD44 receptors into lipid bilayers, 
allowing HA adsorption behaviour to be studied using techniques 
such as the quartz crystal microbalance and ellipsometry.69 
Mechanical stress generated in a confining matrix has been shown 
to control tumour spheroid shape and morphology.70 A logical 50 
inference from this observation is that the material constituents of 
the ECM can influence the growth behaviour of a tumour. It is one 
thing measuring the mechanics/material properties of ECM 
components but novel approaches are required to study the 
material properties of HA in the pericellular matrix (PCM), the 55 
micron scale coating that surrounds many cells and has been 
implicated in many of the physical processes associated with 
disease progression. One such technique is the use of particle 
tracking microrheology (to obtain a mechanical map of PCM) 
combined with fluorescence microscopy, (to identify the 60 
biomolecular constituents). .71 
 
 
 
 65 
Fig. 3 Hyaluronan mediated rolling and adhesion of flowing tumour cells. 
CD44 receptors on both the tumour cells and blood vessel epithelial cells 
bind to hyaluronan. Weak attachment promotes rolling behaviour. Strong 
attachment can lead to full adhesion followed by extravasation though the 
blood vessel wall, a critical step in the establishment of a metastasis. 70 
Elevated levels of hyaluronan 
A paradox exists between the high levels of HA found in the naked 
mole rat, the presence of which is attributed to the prevention of 
cancer, and the high levels of HA associated with cancerous tissues 
in humans, an indicator of poor prognosis. In order to understand 75 
this fundamental issue one must consider what causes an 
accumulation of HA in human tumours. In healthy tissue there is a 
balance between HA synthesis and its degradation. For the naked 
mole rat HA is of the ultra-high molecular weight variety, whereas 
in human cancers, the molecular weight is much lower. In some 80 
cancers (squamous cell carcinoma and melanoma), HA levels 
overall are low and linked to metastatic potential72,73, whereas in 
other cancers such as breast74 and lung adenocarcinomas75, HA 
accumulation is high, but clinical outcomes are still poor.76,77 The 
levels of HA are assessed using histochemical staining.  For 85 
example a HA positive tumour having 71-100% of cells stained 
positive for pericellular HA would be classified as high, and a 
tumour categorised as having reduced HA having 0-70% HA 
positive pericellular stainingcells. The preciseactual concentration 
of HA in various tumours has notn't been determined and methods 90 
for quantification of high versus low HA tumour content vary 
among the literature. Several theories have developed explaining 
the role of HA in a poor prognosis in cancer. The first is that some 
cancer cell types overexpress enzymes such as MMP's that 
breakdown the ECM and the HA-CD44 bond to facilitate invasion 95 
and metastasis.78 The second is that there are particular cancer cells 
that can overexpress HA in response to chemotherapy, thereby 
producing a protective effect for the tumour.79 A further concept is 
that the presence of large amounts of HA can prevent 
chemotherapeutic agents accessing the cancer cells.80 In order to 100 
illustrate the first theory, Fig. 4 presents a magnetic resonance 
image (MRI) of a large malignant tumour in the thigh of a patient 
subsequently diagnosed with a sarcoma. Sarcomas are rare cancers 
arising in the connective tissues and usually appear in the limbs. 
Alongside the MRI is the pathology slide from the tumour. The 105 
lighter grey colour of the tumour in the MRI is due to the large 
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numbers of rapidly dividing cancer cells and the relatively high 
glycosaminoglycan content, mainly HA, in the ECM.81 The cells 
in the pathology image are stained for a matrix metalloproteinase 
enzyme which cleaves the HA receptor CD44. In this tumour there 
is intense MMP staining because the cells are constantly destroying 5 
their microenvironment using these enzymes to cleave key ECM 
components such as collagen and HA. This HA release via initial 
cleavage of the CD44/HA complex followed by further HA 
breakdown into smaller fragments will further promote the 
metastasis of cancer cells via the facilitation of cancer cell 10 
migration.37 Moreover it has been demonstrated that the HA 
fragments themselves can begin a positive feedback loop whereby 
their very presence increases production of CD44 cleaving 
enzymes.82,83  
 15 
Fig. 4 (A). Magnetic Resonance Image of a soft tissue tumour in the thigh. 
The lighter grey appearance of the tumour is due to the high cellular 
content and different ECM components of the tumour compared to the 
bone, normal fascial tissue and fat. Scale bar=20mm. (B) Histological 
section of the interface between the tumour and normal tissues. The 20 
intense brown staining in the cancer cells is due to high expression of the 
invasive enzyme membrane type-1 matrix metalloproteinase. This 
enzyme cleaves the hyaluronan receptor CD44. Scale bar=50µm. 
Abundance of HA in tumours has been found to have serious 
implications in the delivery of therapy. Such HA related resistance 25 
is usually cancer and drug dependent. Examples include resistance 
to Adriamycin in head and neck cancer,84 and resistance to  
Carboplatin in ovarian cancer,79   In terms of more recent treatment 
strategies which include utilisation of antibodies to perturb cancer 
function, the accumulation of HA in solid tumours can act as a 30 
barrier to monoclonal antibody therapy.85 In order to mitigate these 
effects, it has been shown that it is possible to minimise drug 
resistance in peripheral nerve sheath tumours by disrupting the 
CD44-HA bond.86 This disruption was achieved by delivering 
small oligosaccharides of HA which could compete for the 35 
receptor sites with the larger HA polymers. 87 
Hyaluronan based nanoparticle therapy 
The use of HA based nanoparticle systems in cancer therapy has 
several advantages over existing formulations including selective 
attachment (via the CD44 receptors of the target cells), the fact that 40 
many carcinomas over-express CD44, and the ease of chemical 
functionalisation.88 
With its intricate role in cancer biology, it is of no surprise that HA 
and the CD44/HA interaction are being targeted as a strategy for 
both disruption and drug delivery. One such approach has been to 45 
load lipid based nanoparticles with HA oligosaccharides with the 
aim of breaching HA barrier found in breast cancers. The HA 
oligosaccharides, in essence HA fragments, compete with the 
native HA for cell surface CD44 receptors.  Moreover these 
oligosaccharide containing particles have the potential to 50 
overcome chemoresistance.89 A related approach has been to graft 
HA lipid vesicles for the delivery of gene silencing RNA designed 
to interfere with key cancer cell signalling pathways. The over-
expression of CD44 receptors on cancer cells results in HA 
accumulation which in turn facilitates the internalisation of the HA 55 
coated vesicles into the cancer cells. Once internalised, the 
interfering RNA renders the cancer cell susceptible to 
chemotherapy.90 HA coating of lipid vesicles containing 
chemotherapeutic agents is relatively straight forward if cationic 
lipids are used. This is because HA has a negative charge and an 60 
ionic exchange mechanism can be exploited. Such a strategy was 
applied to target CD44 positive colon cancer cells.91 As an 
alternative to liposome based strategiese HA decorated polymer 
nanoparticles have been engineered to target CD44 receptors on t 
malignant cell surfaces with the particles being internalised via 65 
receptor mediated endocytosis.92 Such polymer vesicles make use 
of the so called enhanced permeability and retention effect to reach 
the innards of solid tumours.  
One approach to treating skin cancer involved targeting the HA 
itself. This was achieved via a nanoformulation of the HA 70 
degrading enzyme hyaluronidase. Its modus operandi was to 
degrade tumour associated HA reducing the gel like properties of 
the ECM and thus allowing subsequent administration of 
chemotherapy drugs to reach the tumour.93 Given the many 
adverse effects that accumulation of HA has on tumour 75 
progression, depleting the tumour of this antagonistic biopolymer 
presents opportunities for therapy.87 
HA based hydrogels for studying invasion 
Given the role of HA in the ECM, its role in invasion, the process 
by which cancerous cells break through the extracellular matrix, is 80 
directly related to its over-expression. A particularly revealing 
method to study this phenomenon in vitro has involved biologists 
adopting soft matter approaches to mimic the tumour 
microenvironment.94 Using gels of defined compositions to mimic 
the tumour ECM, entrapped cells are observed and their 85 
trajectories through the gel analysed (Fig. 5).95–97 A prime example 
are gels used to mimic ECM in the brain where HA is known to 
play a major role in glioma cell invasion. Rao et al formulated 
composite HA-collagen gels to examine the behaviour of patient 
tumour derived glioblastoma cells 98. They showed that by adding 90 
HA they could increase the modulus of pure collagen hydrogels 
from 300 Pa to greater than 1000 Pa. These gel mechanical 
properties compare favourably to brain tissue reported to have a 
modulus of between 200 and 1000 kPa.99  and Pedron et al 
demonstrated it was possible to regulate glioma cell phenotype 95 
using brain mimetic HA hyrogels.95,100 This approach has been 
generalised to numerous different cancer cell lines allowing a 
comparative study of invasion and suggest that such gels represent 
some of the essential features of the ECM.101 HA in isolation does 
notn't form robust gels therefore one of two strategies are used to 100 
overcome this limitation . The first is chemical modification of 
hyaluronanHA so that it can form the covalent cross links 
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necessary for gel formation. Methods to create such crosslinkable 
HA involves targeting either carboxiylic acid or hydroxyl 
groups..102 A second strategy is to combine HA with a component 
that does readily form robust gels. Collagen is often used for this 
purpose and has the added value that it is also an extracellular 5 
matrix component.103 Commercially available gels derived from  
tumour secretions are also useful models and have been utilised to 
demonstrate that the HA-CD44 interaction facilitates invasion of 
colon carcinoma cells.104 These gels also allow the relationship 
between matrix mechanical properties and cell behaviour to be 10 
investigated. For example Shen et al were able to show that the 
stiffer the HA hydrogel, the less cancer cell invasion was 
observed.105 This was  highly consistent with the general findings 
that cells can respond to the stiffness of their ECM.106 In order to 
further exploit the soft matter properties of model systems, 15 
researchers have attempted to recreate the tumour 
microenvironment using a combination of lipid bilayerhydrogels,  
and HA and growth factors.107 They were able to grow tumouroids 
from prostate cancer cells and tune the mechanical properties of 
the gels to simulate the microenvironment.  The gels produced had 20 
an average modulus of 234 ± 30 Pa and importantly could be 
degraded by hyaluronidase, the hyaluronanHA digesting enzyme. 
 
 
 25 
Fig. 5 Hyaluronan gels used for cell invasion studies. (A) The gel is 
composed of hyaluronan that has either been chemically modified to 
cross link, or mixed with another gel forming polymer such as collagen. (B) 
Cells of interest are cultured inside the gels, they are observed over time. 
(C) Depending on the type of cancer the cells will digest the gel 30 
components and spread out, simulating invasion of the cancer through 
the ECM. 
 
Perspective 
Understanding the soft matter properties of hyaluronan in the 35 
context of its role in cancer remains a challenge due to both the 
complexity of biological systems and the disease itself. However 
simplified model systems such as gels and microfluidic assays can 
reveal the physics of HA mediated process, many of which are 
involved in various stages of metastasis. Moreover gels can be 40 
tuned to have similar mechanical properties to the extracellular 
matrix, allowing the effect of mechanics on cell invasion and 
model tumour growth to be investigated. As these gel based 
systems become more complex by incorporating additional 
components of the ECM, the studies will become more accurate in 45 
replicating in vivo behaviour.  Nanoparticle base formulations 
exploiting HA-receptor interactions and targeting HA itself offer 
the potential to modify the tumour microenvironment. This could 
be advantageous both for disease treatment and reducing tumour 
resistance to chemotherapy.  50 
It is obvious that a large gap in knowledge exists in terms of 
quantifying and physical characterisation of HA from the tumour 
microenvironment. To date quantification has been performed in a 
histological sense, rather than a physically accurate method 
involving polymer physics. This leaves a gap for soft matter 55 
scientists to work with clinicians in order to extract and 
characterise HA from the tumour microenvironment. 
The mechanisms by which ultra- high molecular weight HA 
confers its anti-cancer properties in the naked mole rat may involve 
several different routes, both signal based and physical in origin.108 60 
However from a soft matter perspective a tantalising question 
remains, what is the significance of the molecular weight of NMR-
HA and how could this be exploited to treat human cancer?  
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